SEC Comment Letter for ALBIREO PHARMA, INC. (CIK 0001322505) — Aug 13, 2020
ALBIREO PHARMA, INC. (CIK 0001322505)
Date: Aug. 13, 2020 · CIK: 0001322505 · Accession: 0000000000-20-007429
AI Filing Summary & Sentiment
File numbers found in text: 333-241680
Letter
United States securities and exchange commission logo August 13, 2020 Ronald H.W. Cooper Chief Executive Officer Albireo Pharma, Inc. 10 Post Office Square, Suite 1000 Boston, MA 02109 Re:Albireo Pharma, Inc. Registration Statement on Form S-3 Filed August 6, 2020 File No. 333-241680 Dear Mr. Cooper: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at 202-551-3798 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Megan Gates, Esq.
Show Raw Text
United States securities and exchange commission logo
August 13, 2020
Ronald H.W. Cooper
Chief Executive Officer
Albireo Pharma, Inc.
10 Post Office Square, Suite 1000
Boston, MA 02109
Re:Albireo Pharma, Inc.
Registration Statement on Form S-3
Filed August 6, 2020
File No. 333-241680
Dear Mr. Cooper:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at 202-551-3798 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Megan Gates, Esq.